Enoxaparin sodium
- Generic Name
- Enoxaparin sodium
- Brand Names
- Lovenox, Inhixa
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 9005-49-6
- Unique Ingredient Identifier
- E47C0NF7LV
- Background
Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hosp...
- Indication
Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.
...
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction With ST Segment Elevation, Deep Vein Thrombosis, Ischemic complications caused by non-q wave myocardial infarction, Ischemic complications caused by unstable angina
- Associated Therapies
- Percutaneous Coronary Intervention (PCI)
Evaluation of the Efficacy of an inTerdialytic "Ethanol 40% v/v - enoxapaRin 1000 U/mL" Lock solutioN to Prevent Tunnelled Catheter Infections in Chronic Hemodialysis Patients
- Conditions
- Interventions
- First Posted Date
- 2017-03-17
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- University Hospital, Clermont-Ferrand
- Target Recruit Count
- 400
- Registration Number
- NCT03083184
- Locations
- 🇫🇷
CHU Clermont-Ferrand, Clermont-Ferrand, France
Catheter-Related Early Thromboprophylaxis With Enoxaparin (CRETE) Trial
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2020-07-13
- Lead Sponsor
- Yale University
- Target Recruit Count
- 51
- Registration Number
- NCT03003390
- Locations
- 🇺🇸
Saint Louis Children's Hospital-Washington University School of Medicine-, Saint Louis, Missouri, United States
🇺🇸Maria Fareri Children's Hospital, Valhalla, New York, United States
🇺🇸Yale University Yale New Haven Health, New Haven, Connecticut, United States
A Study to Evaluate Safety of Single Doses of BMS-986177 in Patients With End Stage Renal Disease (ESRD) Treated With Hemodialysis
- Conditions
- Interventions
- First Posted Date
- 2016-12-22
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 32
- Registration Number
- NCT03000673
- Locations
- 🇺🇸
Davita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism
- Conditions
- Interventions
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 134
- Registration Number
- NCT02923115
- Locations
- 🇳🇱
Albert Schweitzer Hospital, Dordrecht, Netherlands
🇺🇸University of California, San Diego (UCSD) Medical Center, San Diego, California, United States
🇺🇸Duke University Medical Center (DUMC), Durham, North Carolina, United States
Topical Tranexamic Acid and Floseal® in Total Knee Arthroplasty
- Conditions
- Interventions
- First Posted Date
- 2016-08-12
- Last Posted Date
- 2016-08-12
- Lead Sponsor
- Chang Gung Memorial Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT02865174
- Locations
- 🇨🇳
Kaohsiung Chang Gung Memorial Hospital, Koahsiung, Taiwan
Bemiparin Versus Enoxaparin in the Prevention of Venous Thromboembolism Among ICU Patients
- First Posted Date
- 2016-06-09
- Last Posted Date
- 2016-06-10
- Lead Sponsor
- Mohamed Sayed Mohamed Abbas
- Target Recruit Count
- 100
- Registration Number
- NCT02795065
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 811
- Registration Number
- NCT02744092
- Locations
- 🇺🇸
Washington Hospital, Fremont, California, United States
🇺🇸Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States
🇺🇸Saint Joseph's Medical Center, Stockton, California, United States
Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients
- First Posted Date
- 2016-03-11
- Last Posted Date
- 2021-07-08
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 50
- Registration Number
- NCT02706249
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
Comparison Between Effect of Enoxaparin and Clopidogrel on Improving Pregnancy Rate in ICSI
- First Posted Date
- 2016-03-02
- Last Posted Date
- 2016-03-02
- Lead Sponsor
- Ain Shams Maternity Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT02696330
- Locations
- 🇪🇬
Ain Shams maternity hospital, Cairo, Egypt
Low-molecular-weight Heparin in Constituted Vascular Intrauterine Growth Restriction
- First Posted Date
- 2016-02-03
- Last Posted Date
- 2020-03-20
- Target Recruit Count
- 82
- Registration Number
- NCT02672566
- Locations
- 🇫🇷
Hopital Croix Rousse Lyon, Lyon, France
🇫🇷Ch Lyon Sud Pierre Benite, Lyon, France
🇫🇷Chu Grenoble, Grenoble, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.